Fidelity Investments
TRAW icon

Fidelity Investments’s Traws Pharma TRAW Stock Holding History

Fidelity Investments’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42 Buy
23
+21
+1,050% +$39 ﹤0.01% 5305
2025
Q4 		$2 Hold
2
– – ﹤0.01% 5404
2025
Q3 		$4 Hold
2
– – ﹤0.01% 5351
2025
Q2 		$3 Hold
2
– – ﹤0.01% 5305
2025
Q1 		$5 Buy
+2
New +$10 ﹤0.01% 5261
2024
Q3 		– Hold
0
– – – 5765
2024
Q2 		– Sell
-40
Closed -$645 – 5676
2024
Q1 		$1.01K Buy
+40
New +$771 ﹤0.01% 4780
2023
Q3 		– Hold
0
– -$4 – 5556
2023
Q2 		– Hold
0
– – – 5324
2023
Q1 		– Hold
0
– – – 5243
2021
Q4 		– Sell
-16
Closed -$2K – 5015
2021
Q3 		$2K Buy
+16
New +$2.06K ﹤0.01% 4061
2014
Q4 		– Sell
-3
Closed -$615K – 2851
2014
Q3 		$615K Sell
3
-1
-25% -$285K ﹤0.01% 2601
2014
Q2 		$1.2M Sell
4
-9
-69% -$2.66M ﹤0.01% 2482
2014
Q1 		$4.79M Sell
13
-4
-24% -$2.41M ﹤0.01% 2219
2013
Q4 		$10.7M Buy
17
+11
+183% +$10.4M ﹤0.01% 1947
2013
Q3 		$8.56M Buy
+6
New +$8.58M ﹤0.01% 2001

Other funds holding TRAW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments's TRAW Position: Q1 2026 in Review

Fidelity Investments increased its Traws Pharma (TRAW) stake by 1,050% in Q1 2026, buying an estimated $39 and bringing the position to 23 shares worth $42. The position accounts for ﹤0.01% of the portfolio, ranked #5305.

Fidelity Investments first reported a position in TRAW in Q3 2013 and has held it in 12 quarters since. The position peaked at $10.7M in Q4 2013. 28 funds tracked by Wall St. Rank hold TRAW as of Q1 2026.

  • Fidelity Investments held 23 shares of Traws Pharma worth $42 as of Q1 2026.
  • Fidelity Investments bought 21 Traws Pharma shares in Q1 2026, an estimated $39.
  • Traws Pharma made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5305 holding.
  • Fidelity Investments first reported a position in Traws Pharma in Q3 2013 and has held it in 12 quarters since.
  • Fidelity Investments's Traws Pharma position peaked at $10.7M in Q4 2013.
  • 28 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.